サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1423062

トラベルワクチン市場：組成、疾患、地域別レポート、2024年～2032年

Travel Vaccines Market Report by Composition, Disease, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 139 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
トラベルワクチン市場：組成、疾患、地域別レポート、2024年～2032年
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 139 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のトラベルワクチン市場規模は2023年に40億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて9.6%の成長率（CAGR）を示し、2032年までに94億米ドルに達すると予測しています。同市場は、エキゾチックで人里離れた旅行体験に対する需要の高まり、公衆衛生プログラムの一環として国民に無料の旅行用予防接種を提供する政府の取り組み、疾病パターンの変化や新たな脅威の出現などにより、着実な成長を遂げています。

トラベルワクチン市場の分析：

市場の成長と規模同市場は力強い成長を遂げており、これは海外旅行活動の増加に起因しています。また、旅行関連疾患に対する大衆の意識の高まりが市場成長を後押ししています。

技術の進歩：より便利で効果的な製剤のイントロダクションなど、ワクチン開発における技術革新は、旅行者をより確実に保護します。

産業用途：トラベルワクチンは、様々な病気に対する予防を提供するため、レジャー・出張どちらの旅行者にとっても極めて重要です。

地域別動向：北米は、旅行中の健康と安全に重点を置いており、市場をリードしています。しかし、多様な目的地があり、海外からの旅行者が多い欧州が急成長市場として浮上しています。

競合情勢：市場の主要プレーヤーは戦略的イニシアティブに積極的に取り組んでいます。ワクチン・ポートフォリオの拡充、旅行関連の新たな健康リスクへの対応、既存のワクチンの効能強化のため、研究開発（R&D）活動に投資しています。

課題と機会：市場は、ワクチン接種のためらいや規制上のハードルといった課題に直面する一方で、ワクチンへのアクセスの拡大や特定地域に合わせたワクチンソリューションといった機会にも遭遇しています。

将来の展望：ワクチン製造の研究開発（R&D）が進んでおり、渡航用ワクチン市場の将来は有望です。さらに、渡航前相談のためのデジタルヘルスソリューションの採用は、市場の成長を促進すると予想されます。

トラベルワクチン市場の動向：

海外旅行の増加

世界中の大衆の間で海外旅行が増加していることが、市場の成長を支えています。世界化と旅行へのアクセスの利便性が高まるにつれ、世界各地で感染症にさらされるリスクが高まっています。旅行者は、ヘルスケアの水準や疾病の流行が異なる目的地に足を踏み入れるため、予防接種は極めて重要な予防措置となっています。この動向は、レジャー旅行、ビジネス旅行、海外留学の増加によってさらに後押しされています。さらに、エキゾチックで人里離れた旅行を体験したいという願望が、独特の健康リスクのある地域を探検する個人を導き、特殊なワクチンの必要性を強調しています。旅行中の健康予防に対する個人の意識の高まりは、海外旅行者向けのワクチンの重要性を際立たせており、市場の見通しは良好です。

政府の取り組みと規制

政府の取り組みと規制は、市場の牽引役として極めて重要な役割を果たしています。多くの国が、公衆衛生を守り、海外旅行による疾病の蔓延を防ぐことの重要性を認識しています。その結果、いくつかの国の行政機関は、渡航予防接種に関する厳しい規制や勧告を実施しています。これらの規制は、国境を出入りする旅行者、特に病気のリスクが知られている目的地への旅行者に対して、特定の予防接種を義務付けていることが多いです。世界保健機関（WHO）による国際保健規則（IHR）では、特定の国を訪れる旅行者に黄熱病の予防接種の証明を義務付けています。さらに、一部の政府は、公衆衛生プログラムの一環として、国民に旅行用の予防接種を補助または無料で提供しています。こうした規制や取り組みは、旅行者に法的要件を課すだけでなく、トラベルワクチンの必要性に対する認識を高め、市場の需要を促進しています。

世界の疾病の発生と流行

世界の疾病の流行やパンデミックは、市場の牽引役として大きな影響を及ぼしています。こうした出来事は旅行者や政府を勇気づけ、海外旅行に伴う潜在的な健康リスクを浮き彫りにしています。このような大流行への対応として、特定の地域で流行している特定の感染症を予防できるワクチンの需要が高まっています。疾病の流行やパンデミックは、ウイルスの蔓延を緩和し、安全な旅行を促進するワクチンの開発や配布につながっています。旅行者は、自分自身や他人を守るために予防接種の必要性を意識するようになり、トラベルワクチンの普及につながっています。各国政府や国際保健機関も、アウトブレイクを予防・制御する重要な手段としてワクチンの重要性を強調し、渡航前にワクチン接種を受けるよう渡航者に奨励しています。

疾病パターンの変化と新たな脅威

疾病パターンのダイナミックな性質と新たな感染脅威の出現が、市場の成長を強化しています。感染症は静的なものではなく、進化し、変異し、新しい地域に広がっていく。このように刻々と変化する情勢から、進化する病原体と闘うためのワクチンの研究開発（R&D）活動を継続する必要があります。ジカウイルスやエボラ出血熱のような病気は、近年、旅行者にとって重大な懸念事項として浮上しており、これらの脅威に対処するための特定のワクチンの開発を促しています。このような疾病パターンの変化に対する意識は、情報へのアクセスの容易さとともに、旅に出る前に予防接種によって身を守ろうとする個人の行動を促しています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界のトラベルワクチン市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場内訳：組成別
  • 市場内訳：疾患別
  • 市場内訳：地域別
  • 市場予測

第6章 市場内訳：組成別

  • モノワクチン
    • 市場動向
    • 市場予測
  • 混合ワクチン
    • 市場動向
    • 市場予測

第7章 市場内訳：疾患別

  • A型肝炎
    • 市場動向
    • 市場予測
  • DPT
    • 市場動向
    • 市場予測
  • 黄熱病
    • 市場動向
    • 市場予測
  • 腸チフス
    • 市場動向
    • 市場予測
  • B型肝炎
    • 市場動向
    • 市場予測
  • 麻疹・流行性耳下腺炎
    • 市場動向
    • 市場予測
  • 狂犬病
    • 市場動向
    • 市場予測
  • 髄膜炎菌
    • 市場動向
    • 市場予測
  • 水痘
    • 市場動向
    • 市場予測
  • 日本脳炎
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：地域別

  • 北米
    • 市場動向
    • 市場予測
  • 欧州
    • 市場動向
    • 市場予測
  • アジア太平洋
    • 市場動向
    • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場予測
  • ラテンアメリカ
    • 市場動向
    • 市場予測

第9章 世界のトラベルワクチン産業：SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 世界のトラベルワクチン産業：バリューチェーン分析

  • 探索段階
  • 前臨床および臨床開発
  • 薬事承認
  • 製造
  • マーケティングと流通

第11章 世界のトラベルワクチン産業：ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 世界のトラベルワクチン産業価格分析

第13章 トラベルワクチンの製造工程

  • 製品概要
  • 原材料要件
  • 製造プロセス
  • 主な成功要因とリスク要因

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • GlaxoSmithKline Pharmaceuticals Limited
    • Sanofi Pasteur
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • ALK-Abello A/S
    • Bavarian Nordic A/S
    • Crucell（Subsidiary of Johnson & Johnson）
    • CSL Limited
    • AstraZeneca PLC
    • Altimmune, Inc.
    • Abbott Laboratories
    • Hoffmann-La Roche, Inc.
図表

List of Figures

  • Figure 1: Global: Travel Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Travel Vaccines Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Travel Vaccines Market: Breakup by Composition (in %), 2023
  • Figure 4: Global: Travel Vaccines Market: Breakup by Disease (in %), 2023
  • Figure 5: Global: Travel Vaccines Market: Breakup by Region (in %), 2023
  • Figure 6: Global: Travel Vaccines Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: Travel Vaccines Industry: SWOT Analysis
  • Figure 8: Global: Travel Vaccines Industry: Value Chain Analysis
  • Figure 9: Global: Travel Vaccines Industry: Porter's Five Forces Analysis
  • Figure 10: Global: Travel Vaccines (Mono Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Travel Vaccines (Mono Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Travel Vaccines (Combination Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Travel Vaccines (Combination Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Travel Vaccines (Hepatitis A) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Travel Vaccines (Hepatitis A) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Travel Vaccines (DPT) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Travel Vaccines (DPT) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Travel Vaccines (Yellow Fever) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Travel Vaccines (Yellow Fever) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Travel Vaccines (Typhoid) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Travel Vaccines (Typhoid) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Travel Vaccines (Hepatitis B) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Travel Vaccines (Hepatitis B) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Travel Vaccines (Measles and Mumps) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Travel Vaccines (Measles and Mumps) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Travel Vaccines (Rabies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Travel Vaccines (Rabies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Travel Vaccines (Meningococcal) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Travel Vaccines (Meningococcal) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Travel Vaccines (Varicella) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Travel Vaccines (Varicella) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Travel Vaccines (Japanese Encephalitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Travel Vaccines (Japanese Encephalitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Travel Vaccines (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Travel Vaccines (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: North America: Travel Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: North America: Travel Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Europe: Travel Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Europe: Travel Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Asia Pacific: Travel Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Asia Pacific: Travel Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Middle East and Africa: Travel Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Middle East and Africa: Travel Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Latin America: Travel Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Latin America: Travel Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Travel Vaccines Manufacturing: Process Flow

List of Tables

  • Table 1: Global: Travel Vaccines Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Travel Vaccines Market Forecast: Breakup by Composition (in Million US$), 2024-2032
  • Table 3: Global: Travel Vaccines Market Forecast: Breakup by Disease (in Million US$), 2024-2032
  • Table 4: Global: Travel Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Travel Vaccines: Raw Material Requirements
  • Table 6: Global: Travel Vaccines Market Structure
  • Table 7: Global: Travel Vaccines Market: Key Players
目次
Product Code: SR112024A1155

Abstract

The global travel vaccines market size reached US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.6% during 2024-2032. The market is experiencing steady growth driven by the escalating demand for exotic and off-the-beaten-path travel experiences, government initiatives to provide free travel vaccinations to their citizens as part of public health programs, and changing disease patterns and emerging threats.

Travel Vaccines Market Analysis:

Market Growth and Size: The market is witnessing strong growth, which can be attributed to increasing international travel activities. In addition, the rising awareness among the masses about travel-related diseases is bolstering the market growth.

Technological Advancements: Innovations in vaccine development, such as the introduction of more convenient and effective formulations, is ensuring better protection for travelers.

Industry Applications: Travel vaccines are crucial for both leisure and business travelers, as they offer protection against various diseases.

Geographical Trends: North America leads the market, on account of its strong emphasis on health and safety during travel. However, Europe is emerging as a fast-growing market, driven by its diverse range of destinations and a large number of international travelers.

Competitive Landscape: Key players in the market are actively engaged in strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks, and enhancing existing efficacy of vaccines.

Challenges and Opportunities: While the market faces challenges, such as vaccine hesitancy and regulatory hurdles, it also encounters opportunities in expanding vaccine accessibility and tailored vaccine solutions for specific regions.

Future Outlook: The future of the travel vaccines market looks promising, with ongoing research and development (R&D) activities in vaccine production. Moreover, the adoption of digital health solutions for pre-travel consultations is expected to propel the growth of the market.

Travel Vaccines Market Trends:

Rising international travel

The increasing international travel among the masses around the world is supporting the growth of the market. As globalization and accessibility to travel are growing, the risk of exposure to infectious diseases in various parts of the world is rising. Travelers are venturing to destinations with varying healthcare standards and disease prevalence, making vaccinations a crucial precaution. This trend is further bolstered by the growth of leisure travel, business travel, and international students studying abroad. Moreover, the desire for exotic and off-the-beaten-path travel experiences is leading individuals to explore regions with unique health risks, emphasizing the need for specialized vaccines. The growing awareness among individuals about health precautions while traveling is underscoring the importance of vaccines for international travelers, which is offering a favorable market outlook.

Government initiatives and regulations

Government initiatives and regulations play a pivotal role in driving the market. Many countries are recognizing the importance of safeguarding public health and preventing the spread of diseases through international travel. As a result, governing agencies of several countries are implementing stringent regulations and recommendations regarding travel vaccinations. These regulations often mandate certain vaccinations for travelers entering or exiting their borders, especially for destinations with known disease risks. The International Health Regulations (IHR) by the World Health Organization (WHO) require proof of yellow fever vaccination for travelers visiting certain countries. Additionally, some governments offer subsidized or free travel vaccinations to their citizens as part of public health programs. These regulations and initiatives not only create a legal requirement for travelers but also raise awareness about the necessity of travel vaccines, driving demand in the market.

Global disease outbreaks and pandemics

Global disease outbreaks and pandemics have a profound impact on driving the market. These events are encouraging travelers and governments, highlighting the potential health risks associated with international travel. In response to such outbreaks, there is an escalating demand for vaccines that can protect against specific infectious diseases prevalent in certain regions. Disease outbreaks and pandemics are leading to the development and distribution of vaccines to mitigate the spread of the virus and facilitate safe travel. Travelers are becoming more conscious about the need for vaccinations to protect themselves and others, leading to greater adoption of travel vaccines. Governments and international health organizations also emphasize the importance of vaccines as a key tool in preventing and controlling outbreaks, encouraging travelers to be vaccinated before embarking on their journeys.

Changing disease patterns and emerging threats

The dynamic nature of disease patterns and the emergence of new infectious threats are strengthening the growth of the market. Infectious diseases are not static, they evolve, mutate, and spread to new regions. This ever-changing landscape necessitates ongoing research and development (R&D) activities of vaccines to combat evolving pathogens. Diseases like Zika virus and Ebola are emerging as significant concerns for travelers in recent years, prompting the development of specific vaccines to address these threats. This awareness of changing disease patterns, along with the ease of accessing information, is encouraging individuals to seek protection through vaccinations before embarking on their journeys.

Travel Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on composition and disease.

Breakup by Composition:

Mono Vaccines

Combination Vaccines

Combination vaccines account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the composition. This includes mono vaccines and combination vaccines. According to the report, combination vaccines represented the largest segment.

Combination vaccines offer the convenience of protecting against multiple diseases with a single injection. Popular combination vaccines include those that guard against hepatitis A and B, as well as typhoid. The primary advantage of combination vaccines is their efficiency in providing comprehensive protection, simplifying the vaccination process for travelers. This convenience is especially appealing to individuals who plan to visit regions with multiple disease risks, reducing the number of shots required. The combination vaccines segment is growing due to increased demand for streamlined vaccination regimens and improved compliance among travelers seeking a one-shot solution for their health needs.

Mono vaccines consist of individual vaccines targeting specific diseases. These vaccines are designed to provide protection against a single infectious agent, such as hepatitis A, hepatitis B, or typhoid. Mono vaccines are often recommended when travelers are visiting regions with a particularly high risk of one specific disease. They offer the advantage of targeted protection, allowing travelers to customize their vaccination regimen based on their destination and individual health needs.

Breakup by Disease:

Hepatitis A

DPT

Yellow Fever

Typhoid

Hepatitis B

Measles and Mumps

Rabies

Meningococcal

Varicella

Japanese Encephalitis

Others

Hepatitis A represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the disease. This includes hepatitis A, DPT, yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, varicella, Japanese encephalitis, and others. According to the report, hepatitis A represented the largest segment.

Hepatitis A is a highly contagious viral infection that can be contracted through contaminated food or water, making it a significant concern for travelers. This segment includes vaccines that provide immunity against the hepatitis A virus. Due to its prevalence in many travel destinations, hepatitis A vaccination is recommended for individuals traveling to regions with inadequate sanitation and hygiene standards. The prominence of hepatitis A in the market reflects the widespread recognition of its risk and the importance of vaccination for the health and safety of travelers.

DPT vaccines, which protect against diphtheria, pertussis (whooping cough), and tetanus, are another important segment in the travel vaccines market. While these diseases are not exclusive to travel-related risks, they are included in some international vaccination recommendations. Tetanus can be a concern if travelers are exposed to contaminated wounds during their journeys. Therefore, DPT vaccines are essential for ensuring comprehensive protection against these preventable diseases, even when traveling.

Yellow fever vaccines target the prevention of yellow fever, a mosquito-borne viral disease prevalent in certain tropical regions. Travelers visiting countries in Africa and South America where yellow fever is endemic often require proof of vaccination for entry. The yellow fever segment in the travel vaccines market serves travelers who plan to explore these high-risk areas and need to adhere to international health regulations.

Typhoid vaccines are essential for travelers heading to regions with a higher risk of typhoid fever, often linked to contaminated food and water sources. These vaccines protect against Salmonella typhi, the bacterium responsible for typhoid fever. The typhoid segment addresses the specific health needs of travelers venturing to areas with suboptimal sanitation and hygiene conditions.

Hepatitis B vaccines are important for travelers who may engage in activities that carry an elevated risk of exposure to the hepatitis B virus, such as unprotected sexual contact or medical procedures involving needles. While hepatitis B is not exclusive to travel, these vaccines cater to the needs of individuals seeking protection against this virus while away from their home country.

Breakup by Region:

Asia Pacific

North America

Europe

Middle East and Africa

Latin America

North America leads the market, accounting for the largest travel vaccines market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share due to the high level of outbound international travel from the United States and Canada. The region has a strong emphasis on health and safety during travel, and travelers are well-informed about the importance of vaccinations. Additionally, government recommendations and regulations, including those set by the Centers for Disease Control and Prevention (CDC) in the United States, play a significant role in promoting the uptake of travel vaccines. North America also benefits from a well-established healthcare infrastructure and a robust pharmaceutical industry, making travel vaccines readily accessible to the population.

Europe is another substantial market for travel vaccines. With its diverse range of destinations and a large number of international travelers, European countries have a strong demand for travel vaccinations. The European Union is establishing guidelines for travelers, recommending vaccinations based on destination and health history. European travelers tend to be proactive in seeking pre-travel healthcare advice, contributing to the growth of the market in the region.

The Asia Pacific region is experiencing rapid growth in the market due to a rise in outbound tourism and business travel. As economies in the region are expanding, more individuals have the means and desire to explore international destinations. This is resulting in a heightened awareness of travel-related health risks, catalyzing the demand for travel vaccines. Moreover, some countries are becoming popular tourist destinations, leading to an increase in inbound travelers who also require vaccinations.

The Middle East and Africa region also contribute to the market. This segment is driven by both outbound tourism and inbound travelers, as the region hosts various cultural, religious, and business events. Vaccinations are often mandated for individuals traveling to Mecca for Hajj or Umrah, further propelling the market growth. In addition, the presence of diseases like yellow fever and malaria underscores the importance of vaccinations for travelers.

Latin America is another growing market for travel vaccines, driven by increasing outbound travel from countries like Brazil and Mexico. Travelers from these regions often explore destinations within South America, North America, and Europe, necessitating vaccinations for disease prevention.

Leading Key Players in the Travel Vaccines Industry:

Key players in the market are actively engaged in several strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks and enhancing existing efficacy of vaccines. These companies are also focusing on increasing their global distribution networks to ensure accessibility to travel vaccines in diverse regions. Furthermore, they collaborate with healthcare providers, government agencies, and international health organizations to promote vaccination awareness and education among travelers. Additionally, pharmaceutical firms are exploring innovative vaccine delivery methods, such as oral or patch-based vaccines, to improve convenience and compliance for travelers. Overall, key players are dedicated to advancing the field of travel vaccines to meet the evolving needs of global travelers effectively.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

GlaxoSmithKline Pharmaceuticals Limited

Sanofi Pasteur

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

ALK-Abello A/S

Bavarian Nordic A/S

Crucell (Subsidiary of Johnson & Johnson)

CSL Limited

AstraZeneca PLC

Altimmune, Inc.

Abbott Laboratories

Hoffmann-La Roche, Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

March 31, 2021: Sanofi Pasteur announced a huge investment in a new vaccine manufacturing facility at its existing site in Toronto, Canada. The investment in a new facility will provide additional antigen and filling capacity for Sanofi's Fluzone® High-Dose Quadrivalent influenza vaccine, helping to increase supply availability in Canada, the United States and Europe.

January 5, 2022: Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.

June 1, 2021: Merck & Co., Inc. announced that Vaxelis vaccine, developed as a part of a U.S. based partnership between Merck and Sanofi Pasteur is now available in the U.S. VAXELIS is the first and only hexavalent (six-in-one) combination vaccine available in the U.S. indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B.

Key Questions Answered in This Report

  • 1. What is the size of the global travel vaccines market in 2023?
  • 2. What is the expected growth rate of the global travel vaccines market during 2024-2032?
  • 3. What are the key factors driving the global travel vaccines market?
  • 4. What has been the impact of COVID-19 on the global travel vaccines market?
  • 5. What is the breakup of the global travel vaccines market based on the composition?
  • 6. What is the breakup of the global travel vaccines market based on the disease?
  • 7. What are the key regions in the global travel vaccines market?
  • 8. Who are the key companies/players in the global travel vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Travel Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Composition
  • 5.5 Market Breakup by Disease
  • 5.6 Market Breakup by Region
  • 5.7 Market Forecast

6 Market Breakup by Composition

  • 6.1 Mono Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Combination Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Disease

  • 7.1 Hepatitis A
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 DPT
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Yellow Fever
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Typhoid
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Hepatitis B
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Measles and Mumps
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Rabies
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Meningococcal
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast
  • 7.9 Varicella
    • 7.9.1 Market Trends
    • 7.9.2 Market Forecast
  • 7.10 Japanese Encephalitis
    • 7.10.1 Market Trends
    • 7.10.2 Market Forecast
  • 7.11 Others
    • 7.11.1 Market Trends
    • 7.12.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia Pacific
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Middle East and Africa
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Latin America
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Global Travel Vaccines Industry: SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Global Travel Vaccines Industry: Value Chain Analysis

  • 10.1 Exploratory Stage
  • 10.2 Preclinical and Clinical Development
  • 10.3 Regulatory Approval
  • 10.4 Manufacturing
  • 10.5 Marketing and Distribution

11 Global Travel Vaccines Industry: Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Global Travel Vaccines Industry: Price Analysis

13 Travel Vaccines Manufacturing Process

  • 13.1 Product Overview
  • 13.2 Raw Material Requirements
  • 13.3 Manufacturing Process
  • 13.4 Key Success and Risk Factors

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 GlaxoSmithKline Pharmaceuticals Limited
    • 14.3.2 Sanofi Pasteur
    • 14.3.3 Merck & Co., Inc.
    • 14.3.4 Novartis AG
    • 14.3.5 Pfizer Inc.
    • 14.3.6 ALK-Abello A/S
    • 14.3.7 Bavarian Nordic A/S
    • 14.3.8 Crucell (Subsidiary of Johnson & Johnson)
    • 14.3.9 CSL Limited
    • 14.3.10 AstraZeneca PLC
    • 14.3.11 Altimmune, Inc.
    • 14.3.12 Abbott Laboratories
    • 14.3.13 Hoffmann-La Roche, Inc.